3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
9
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
13
Gastrointestinal
9
Breast
9
Other hematologic neoplasm
7
Thoracic
6
Plasma cell
6
Lymphoid
5
Tumor-Agnostic
4
Head & Neck
4
Gynecologic
4
CNS
4
Dermatologic
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Interventions
Doxorubicin
44
Imatinib Mesylate
33
pembrolizumab
23
Cyclophosphamide
23
Sunitinib
22
Gemcitabine
22
Temozolomide
17
Irinotecan
14
Bevacizumab
14
Docetaxel
13
nilotinib
12
Trabectedin
12
ripretinib
11
pazopanib
11
olaratumab
10
fludarabine
10
eribulin
10
regorafenib
9
avapritinib
9
Fluorouracil
9
Carboplatin
9
Paclitaxel
8
Nivolumab
8
Ifosfamide
8
Ibandronic Acid
8
spartalizumab
7
anlotinib
7
Vincristine
7
Radiation
7
Ipilimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Standard of Care
×
Sarcoma
×
Clear all
NCT05236257
2024-12-10
EPI VITRAKVI
Bayer
Completed
93 enrolled
14 charts